 Galapagos NV NASDAQ: GLPG reported topline results with tyrosine kinase 2 TYK2 inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four out of 10 patients in the high dose group had at least a 50 improvement in severity index PASI 50 from baseline, compared to one out of 10 subjects on placebo. 